CEO Executive AssistantPharma CEO medical affairs strategy time is one of the most consistently underprotected categories in a pharmaceutical chief executive’s schedule. The commercial function demands attention because of its direct revenue connection. The regulatory function demands attention because of its approval risk. Business development demands attention because of its strategic optionality. Medical affairs, with its longer feedback loops and less immediately visible commercial impact, routinely gets crowded out.
This is a strategic error. The medical affairs function is increasingly the determinant of a product’s sustained commercial performance, particularly for specialty and complex products where physician education, real-world evidence, and health economic arguments matter more than promotional reach. A CEO who does not invest in medical affairs strategy is building a commercial platform on a weaker foundation than they realize.
Why Medical Affairs Requires CEO-Level Strategic Direction
Medical affairs exists at the intersection of science and healthcare system influence. The medical science liaison (MSL) field force has access to the key opinion leaders, academic investigators, and community physicians who shape prescribing behavior in ways that a sales force cannot replicate. The HEOR team generates the health economic evidence that payers use to make formulary decisions. The medical education function shapes how physicians understand a disease area and the role of the company’s product within it. Real-world evidence programs generate the post-launch data that either reinforces or undermines the claims made in the pivotal trial.
None of these functions is purely operational. Each of them involves strategic choices with significant commercial and reputational consequences.
Which disease areas does the company invest in from a medical education standpoint? What HEOR analyses does the company fund, and which health system metrics does it use as primary endpoints? How does the company’s MSL program define its engagement priorities, and which physician segments get the most intensive field coverage? How aggressively does the company pursue real-world evidence programs that could either strengthen or complicate the product’s profile?
These are CEO-level strategy questions disguised as functional operational decisions. When the CEO is absent from them, they default to the Chief Medical Officer’s judgment or, in some cases, to what the commercial team wants the medical function to do. Neither of those defaults reliably produces the best strategic outcome.
Separating Medical Affairs Strategy From Commercial Strategy
One of the most consequential organizational principles for a pharmaceutical CEO is maintaining a genuine separation between medical affairs strategy and commercial strategy. This is not merely a compliance obligation (although the regulatory requirements around medical affairs independence are real and enforceable). It is a strategic discipline that produces better outcomes for both functions.
Why Conflation Harms Both Functions
When medical affairs strategy is driven by commercial priorities, the function loses credibility with the scientific and physician community. Key opinion leaders recognize when MSL conversations are primarily promotional. Academic investigators decline medical education collaborations that feel commercially scripted. The HEOR team produces analyses designed to support rebate negotiations rather than to generate genuine insights about product performance in real-world populations.
The result is a medical affairs function that consumes significant resources but generates diminishing returns as its scientific credibility erodes.
When commercial strategy ignores the insights generated by medical affairs, the function produces valuable evidence that never translates into better pricing, stronger formulary positioning, or more effective physician engagement. The commercial team operates on promotional instincts rather than on the richest available evidence about how the product is actually performing.
The CEO’s role is to hold both functions to high standards: ensuring medical affairs has genuine scientific independence while ensuring the commercial function fully integrates the insights that medical affairs generates.
Structuring Separate CEO Touchpoints
A practical implementation: the CEO should have distinct, separately scheduled touchpoints with the Chief Medical Officer and the Chief Commercial Officer, at a cadence that does not allow one to dominate the agenda of the other. Monthly one-on-one sessions with each is a minimum; for companies in active launch phase or with multiple in-line products, biweekly sessions may be warranted.
Critically, the CEO should not routinely convene joint medical affairs and commercial strategy meetings. These meetings tend to resolve into commercial priority, because commercial timelines are more urgent and commercial leaders are typically more assertive in cross-functional settings. Medical affairs strategy deserves its own protected forum.
MSL Program Oversight: What the CEO Should Track
The MSL field force is the medical affairs function’s primary relationship engine. In specialty therapeutics, a well-run MSL program is often more influential than the sales force in shaping the behavior of high-prescribing academic and community specialists. This makes it one of the highest-value investments in the medical affairs budget.
CEO-Level Oversight Indicators
The CEO does not manage the MSL program. The Chief Medical Officer, typically with a VP or Director of Medical Affairs managing the field function, owns the operational details. What the CEO should track are three leading indicators:
MSL engagement depth, measured not by number of interactions but by the quality of scientific dialogue with priority KOLs. Are the MSLs having substantive scientific conversations, or are they executing call plans that mimic a sales force? The CMO should be able to report on this with specific examples, not just aggregate metrics.
Scientific feedback loop quality. One of the primary values of an MSL field force is the intelligence it generates from healthcare provider interactions: signals about unmet needs, competitor activity, emerging resistance patterns, or unanswered clinical questions. If that intelligence is not being systematically captured, analyzed, and reported to the CEO and CMO, the MSL program is operating at a fraction of its potential value.
KOL development pipeline. The scientific community evolves. Established KOLs retire or shift focus; emerging academic investigators build prominence. The CEO should understand whether the MSL program has a development strategy for the next generation of KOLs, not just maintenance relationships with established figures.
A quarterly 60-to-90-minute medical affairs review that includes a structured update on these three indicators gives the CEO the oversight they need without pulling them into operational MSL management.
Health Economics and Outcomes Research Strategy
HEOR is where medical affairs strategy most directly connects to commercial outcomes. The analyses produced by the HEOR team are the foundation of payer conversations, formulary submissions, and outcomes-based contract negotiations. They are also the basis for real-world evidence publications that influence prescriber confidence in the product.
The CEO’s Investment Decision Role
HEOR programs require investment decisions that carry the same strategic weight as late-stage clinical investments. A large outcomes registry, a health system partnership for electronic health record data access, or a prospective real-world study can cost millions of dollars and take two to three years to generate usable evidence. These decisions require CEO-level authorization and strategic direction.
The question the CEO needs to answer is not “should we invest in HEOR?” (the answer is yes, for any specialty product with ambitions beyond the first formulary cycle). The question is: “What are the two or three specific health economic questions whose answers would most materially improve our market access position over the next three years?” The HEOR team can execute against strategic direction. What they cannot do is manufacture strategic direction on their own.
A practical approach: a dedicated annual HEOR strategy session, separate from the medical affairs operational review, where the CEO and CMO define the three to five HEOR investment priorities for the coming year. This session should include input from the market access team (which questions matter most to payer decision-makers) and from clinical development (which real-world data could strengthen the evidence base beyond the pivotal trials).
Medical Education Priorities
Medical education in pharmaceutical companies encompasses a range of activities: independent medical education grants, disease awareness programs, scientific publications strategy, advisory board programs, symposia at major medical meetings, and digital content for healthcare providers.
These activities shape how physicians understand the disease area and the therapeutic alternatives available to them. Companies that invest thoughtfully in medical education create an environment where their products are understood in their appropriate clinical context. Companies that treat medical education as a promotional tool lose credibility and eventually face regulatory scrutiny.
CEO Involvement in Education Strategy
The CEO’s role in medical education is primarily architectural: ensuring that the company’s medical education investments are aligned with genuine unmet needs in physician knowledge (not primarily with commercial messaging goals), that the independence of educational content is genuinely protected, and that the company’s publications strategy is building a comprehensive scientific narrative rather than cherry-picking favorable data.
Scientific publications deserve specific attention. A publications strategy that consistently delays or avoids publishing inconvenient findings undermines the company’s scientific credibility with exactly the physicians who matter most: the academic specialists who read the primary literature carefully and form the KOL community’s opinion about the company’s scientific rigor.
The CEO should be aware of the company’s publications pipeline and should create an organizational expectation that publication decisions are made on scientific merit, not on whether the data is favorable.
Real-World Evidence Investment
Real-world evidence has become a central element of the post-launch pharmaceutical commercial strategy. Payers increasingly require real-world evidence to justify formulary positioning decisions over time. Regulatory agencies are expanding their acceptance of RWE for label expansions and supplemental approvals. And the prescribing community uses real-world data to evaluate whether pivotal trial results translate to their patient populations.
Protecting R&D time addresses the broader principle of ensuring R&D investments, including post-launch evidence generation, receive appropriate CEO attention.
Building a Durable RWE Program
A real-world evidence program requires infrastructure investment: data access agreements with health systems or registries, analytical capabilities within the HEOR team, a publications and dissemination strategy for the evidence generated, and a timeline that aligns with the points in the commercial lifecycle where the evidence will be most valuable.
The CEO needs to make the infrastructure investment decision, define the strategic priorities for the RWE program (which clinical questions, which patient populations, which health system metrics), and ensure the program is resourced to generate credible evidence rather than underfunded analyses that will not withstand scientific scrutiny.
According to the FDA’s framework for real-world evidence, RWE programs that are designed with scientific rigor from inception generate the most credible evidence for both regulatory and market access applications. This standard requires CEO-level commitment to independent, rigorous program design.
Pharma CEO support explores how effective executive assistance structures protect the CEO’s time for strategic functions like medical affairs while managing the administrative complexity of a cross-functional role.
Structuring the CEO’s Medical Affairs Calendar
Based on the strategic functions described above, a pharma CEO in the commercial stage with one or more specialty products should protect approximately four to six hours per month for medical affairs strategy. This allocation covers:
A monthly one-on-one with the CMO (60 to 90 minutes), covering scientific feedback from field MSL activities, KOL relationship status, active publications and their strategic context, and any emerging HEOR or RWE decisions requiring CEO input.
A quarterly medical affairs strategy session (two to three hours), reviewing the annual HEOR and RWE investment priorities, MSL program performance against strategic objectives, and medical education grant and content priorities for the next quarter.
Selected scientific events, such as relevant medical congress sessions where the company’s data is being presented or where important competitive data is being reported. The CEO does not need to attend every session, but having a direct connection to the scientific discourse at ASCO, ASH, ADA, or other relevant congresses is part of maintaining the scientific credibility that medical affairs requires to function effectively.
Conclusion
Pharma CEO medical affairs strategy time is protected not because it is urgent (commercial fire drills will always feel more urgent) but because its absence compounds over time into a structural commercial weakness. The MSL program loses scientific credibility. The HEOR program lacks strategic direction. Real-world evidence investments are underfunded or misaligned. The publications strategy becomes defensive rather than proactive.
None of these failures happens overnight. They accumulate over 12 to 24 months, and they become visible only when the formulary negotiation is harder than it should be, or when the key opinion leader community’s engagement with the company is noticeably cooler than it was two years ago. The CEOs who protect medical affairs strategy time are the ones who never have to ask why that happened.
Related Reading
For further context, explore How Pharma CEOs Balance Regulatory Affairs and Commercial Time and How Pharma CEOs Manage Time During Major Conference Season.